N-[2-(4-amino-2-oxo-1H-quinolin-3-yl)-3H-benzimidazol-5-yl]-2-(dimethylamino)-N-methylacetamide
C21H22N6O2 — CID 135926104
Data last refreshed: (MolForge compound catalog, from PubChem)
About N-[2-(4-amino-2-oxo-1H-quinolin-3-yl)-3H-benzimidazol-5-yl]-2-(dimethylamino)-N-methylacetamide
N-[2-(4-amino-2-oxo-1H-quinolin-3-yl)-3H-benzimidazol-5-yl]-2-(dimethylamino)-N-methylacetamide (PubChem CID 135926104) has the molecular formula C21H22N6O2 and a molecular weight of 390.45 g/mol. Its IUPAC name is N-[2-(4-amino-2-oxo-1H-quinolin-3-yl)-3H-benzimidazol-5-yl]-2-(dimethylamino)-N-methylacetamide.
Molecular Properties
| Compound Name | N-[2-(4-amino-2-oxo-1H-quinolin-3-yl)-3H-benzimidazol-5-yl]-2-(dimethylamino)-N-methylacetamide |
|---|---|
| PubChem CID | 135926104 |
| Molecular Formula | C21H22N6O2 |
| Molecular Weight | 390.45 g/mol |
| Exact Mass | 390.18 |
| IUPAC Name | N-[2-(4-amino-2-oxo-1H-quinolin-3-yl)-3H-benzimidazol-5-yl]-2-(dimethylamino)-N-methylacetamide |
| SMILES | CN(C)CC(=O)N(C)c1ccc2nc(-c3c(N)c4ccccc4[nH]c3=O)[nH]c2c1 |
| InChI | InChI=1S/C21H22N6O2/c1-26(2)11-17(28)27(3)12-8-9-15-16(10-12)24-20(23-15)18-19(22)13-6-4-5-7-14(13)25-21(18)29/h4-10H,11H2,1-3H3,(H,23,24)(H3,22,25,29) |
| InChIKey | WNVADWMUVOLRPY-UHFFFAOYSA-N |
| XLogP | 2.18 |
| TPSA | 111.11 Ų |
| H-Bond Donors | 3 |
| H-Bond Acceptors | 5 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 29 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 390.45 |
| LogP ≤ 5 | 2.18 |
| H-Bond Donors ≤ 5 | 3 |
| H-Bond Acceptors ≤ 10 | 5 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 135926104 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.